Camila Musa Honorato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Camila Musa Honorato has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Adhemar Longatto-Filho
Medical Laboratory of Medical Investigation (LIM/14), Department of Pathology São Paulo University Faculty of Medicine São Paulo Brazil
1 shared publication - Ana Carla Franco Ubinha
Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos 14784-400, Brazil
1 shared publication - Luciano Ipólito Branquinho
Barretos Cancer Hospital
1 shared publication - Luis Pires de Melo Filho
Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos 14784-400, Brazil
1 shared publication - Marcelo Henrique dos Santos
Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos 14784-400, Brazil
1 shared publication - Ricardo dos Reis
Barretos Cancer Hospital, Department of Gynecologic Oncology, Barretos, Brazil
1 shared publication
Latest Publications
- Open Access
The Impact of the Number of Neoadjuvant Chemotherapy Cycles on Outcomes in Advanced Ovarian Cancer: A Narrative Review
Although standard chemotherapy for three to four cycles followed by surgery is considered safe and effective in the management of advanced ovarian cancer, the impact of extending treatment beyond this period remains uncertain. Some authors suggest that the number of neoadjuvant chemotherapy cycles does not directly affect prognosis and may reflect a confounding bias. Others, however, indicate that a prolonged exposure to chemotherapy can promote the selection of resistant tumor clones, negatively influencing patient survival and disease progression. This review aims to summarize the current evidence on the topic, evaluating the effect of prolonged chemotherapy on surgical cytoreduction and survival. To achieve this, we conducted an analysis of the English-language literature available in PubMed, focusing on treatment duration, achievement of complete surgical resection, survival outcomes, and prognostic factors.
Open AccessThe Impact of the Number of Neoadjuvant Chemotherapy Cycles on Outcomes in Advanced Ovarian Cancer: A Narrative Review
Although standard chemotherapy for three to four cycles followed by surgery is considered safe and effective in the management of advanced ovarian cancer, the impact of extending treatment beyond this period remains uncertain. Some authors suggest that the number of neoadjuvant chemotherapy cycles does not directly affect prognosis and may reflect a confounding bias. Others, however, indicate that a prolonged exposure to chemotherapy can promote the selection of resistant tumor clones, negatively influencing patient survival and disease progression. This review aims to summarize the current evidence on the topic, evaluating the effect of prolonged chemotherapy on surgical cytoreduction and survival. To achieve this, we conducted an analysis of the English-language literature available in PubMed, focusing on treatment duration, achievement of complete surgical resection, survival outcomes, and prognostic factors.